Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(127)
•••
Post by SkywalkerofLukeon Sep 23, 2022 12:50pm
139 Views
Post# 34982272

Recent News

Recent News

A little surprised with AGN.c (a clinical stage Canadian pharmaceutical development company) AGNPF ‘s action as of late considering their recent news. Especially the announcement that they filed a request for Orphan designation which if approved = 7 yrs market exclusivity.


Highlights


- Received a cash payment of approx. $450K from a refundable tax credit program from the clinical research work in Australia

- Filed a request for Orphan Designation with the FDA for the use of Ifenprodil as a treatment for IPF

- Received approval to conduct a Phase 1 clinical study of an intravenous formulation of AP-188 (DMT) for the treatment of stroke (CEO will be speaking about this at the world's largest psychedelic conference Wonderland in Miami in Nov.)

- + more


https://ir.algernonpharmaceuticals.com/news-events

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities